Key Takeaways
- FDA greenlight enables Eli Lilly to market orforglipron under the brand name Foundayo as a once-daily oral weight-loss medication
- LillyDirect will begin distributing Foundayo on April 6 with self-pay pricing set at $149 monthly
- Wall Street forecasts show 2026 revenue between $1.5B (Guggenheim estimate) and $2.8B (Citi projection), with potential peak sales surpassing $40B
- The pharmaceutical company stockpiled $1.5B in inventory ahead of launch to prevent the supply shortages experienced with injectable alternatives
- Consensus analyst price target for LLY stands at $1,221, with the majority assigning Buy or Moderate Buy ratings
Eli Lilly has achieved a major regulatory milestone with FDA clearance for orforglipron, marketed under the brand name Foundayo. This once-daily oral medication represents the company’s entry into pill-based weight management solutions and positions the pharmaceutical giant to compete directly with Novo Nordisk’s market position.
Clinical data demonstrates that Foundayo users achieved body weight reductions ranging from 12% to 15%. The medication works through GLP-1 hormone targeting, employing the same biological pathway utilized by Novo’s Ozempic and Wegovy injectable formulations.
Starting April 6, LillyDirect will make Foundayo available to consumers. The entry-level dose carries a $149 monthly price point for those paying directly — matching the cost structure of Ozempic.
CEO David Ricks announced that regulatory submissions have been filed in over 40 nations, indicating the company’s plans for widespread global distribution.
Financial analysts have responded with optimistic projections. Estimates for 2026 revenue span from $1.5 billion to $2.8 billion, with Citi leading the bullish outlook at $2.8B and suggesting peak annual performance could exceed $40 billion. J.P. Morgan anticipates $6 billion in sales by 2027.
Bernstein adopted a measured perspective on immediate returns, noting that complimentary sampling programs, starting dose protocols and pricing considerations might temper initial revenue generation despite strong prescription growth. The market will focus heavily on weekly new-patient enrollment figures.
Manufacturing advantages also favor Foundayo. Production proves simpler compared to injectable GLP-1 medications, potentially enabling faster scaling — especially valuable in global markets where injectable supply has been constrained.
Inventory Strategy Addresses Past Challenges
Lilly reports accumulating $1.5 billion in pre-launch stock, a strategic move prompted by availability problems that affected Zepbound and Mounjaro injectables. These shortages created opportunities for compounding pharmacies throughout the United States to market alternative versions. The company has pursued legal remedies against compounders and wellness facilities distributing products purporting to contain tirzepatide.
Novo Nordisk has mounted a competitive response through subscription pricing models and product modifications. UBS analysts calculate that oral formulations from both pharmaceutical companies could collectively reach approximately $5 billion in 2026 revenue, establishing a rapidly expanding segment within obesity therapeutics.
Morningstar research suggests oral obesity medications may represent close to one-third of a $180 billion worldwide market by 2034.
Corporate Expansion and Market Sentiment
The company is moving forward with the acquisition of Centessa Pharmaceuticals through a transaction initially priced near $6.3 billion, broadening its therapeutic portfolio into sleep-wake disorders and narcolepsy treatment. A legal firm has initiated an investor investigation regarding the Centessa acquisition process, potentially creating complications before deal completion.
Westend Capital Management established a new LLY position during Q4, acquiring 16,393 shares valued at approximately $17.6 million. The holding now represents roughly 4.9% of Westend’s total portfolio.
Fourth-quarter results showed EPS of $7.54, surpassing the $7.48 consensus, while revenue reached $19.29 billion compared to analyst expectations of $17.85 billion. Year-over-year revenue growth measured 42.6%. Management established FY2026 EPS guidance spanning $33.50 to $35.00.
Among 30 analysts tracking the stock, 23 assign Buy ratings, four recommend Hold, and one rates it Sell. The average price objective reaches $1,221.26.
